Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | DAO | P14920 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | CES2 | O00748 | 2/20 | 0.50 |
| ▸ | CES1 | P23141 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28328354 | 0.86 | TSHR (0.52) | CYP2C9CYP2C19TSHRCYP2D6DAO | |
| SCHEMBL5179085 | 0.83 | TSHR (0.53) | CYP2C9CYP2C19TSHRCYP2D6DAO | |
| SCHEMBL14782239 | 0.83 | CES2 (0.55) | CYP2C9CYP2C19TSHRCYP2D6DAO | |
| SCHEMBL11245259 | 0.82 | CYP2C19 (0.53) | CYP2C9CYP2C19TSHRCYP2D6DAO | |
| SCHEMBL3197028 | 0.81 | TSHR (0.58) | CYP2C9CYP2C19TSHRCYP2D6DAO | |
| SCHEMBL3494961 | 0.81 | HPGD (0.46) | CYP2C9CYP2C19TSHRCYP2D6DAO | |
| SCHEMBL4076327 | 0.80 | CYP2C9 (0.50) | CYP2C9CYP2C19TSHRCYP2D6DAO | |
| SCHEMBL7204541 | 0.80 | RAB9A (0.51) | CYP2C9CYP2C19TSHRCYP2D6RAB9A | |
| SCHEMBL3960975 | 0.80 | TSHR (0.60) | CYP2C9CYP2C19TSHRCYP2D6DAO | |
| SCHEMBL28784111 | 0.79 | TSHR (0.46) | CYP2C9CYP2C19TSHRCYP2D6DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1405917-B1 | Process for the production of 3-Heteroaryl-3-hydroxy-propionic acid derivatives by enantioselective microbial reduction | SALTIGO GMBH (DE) | 2013-08-14 | — | — | EP | claimed |
| EP-1346977-B1 | Method for producing aryl-aminopropanols | SALTIGO GMBH (DE) | 2009-07-22 | — | — | EP | claimed |
| EP-1340746-B1 | Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives | SALTIGO GMBH (DE) | 2007-02-28 | — | — | EP | claimed |
| EP-1405917-A2 | Process for the production of 3-Heteroaryl-3-hydroxy-propionic acid derivatives by enantioselective microbial reduction | Bayer Chemicals AG (DE) | 2004-04-07 | — | — | EP | claimed |
| EP-1346977-A1 | Method for producing aryl-aminopropanols | Bayer Aktiengesellschaft (DE) | 2003-09-24 | — | — | EP | claimed |
| EP-1340746-A1 | Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives | BAYER AG (DE) | 2003-09-03 | — | — | EP | claimed |
| EP-1405917-B1 | Process for the production of 3-Heteroaryl-3-hydroxy-propionic acid derivatives by enantioselective microbial reduction | SALTIGO GMBH (DE) | 2013-08-14 | — | — | EP | disclosed |
| US-20120302587-A1 | RHO-KINASE INHIBITORS | NAGARAHNAM DHANAPALAN (US) | 2012-11-29 | — | — | US | disclosed |
| EP-1470121-B1 | PYRIMIDINE DERIVATIVES AS RHO-KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2012-07-11 | — | — | EP | disclosed |
| US-8129386-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20120053179-A1 | Rho-Kinase Inhibitors | NAGARATHNAM DHANAPALAN (US) | 2012-03-01 | — | — | US | disclosed |
| EP-2042504-B1 | Fused azole-pyrimidine derivatives | BAYER SCHERING PHARMA AG (DE) | 2011-06-01 | — | — | EP | disclosed |
| EP-2169009-B1 | Anthrapyridone dyes, their preparation and their use | ILFORD IMAGING CH GMBH (CH) | 2011-05-25 | — | — | EP | disclosed |
| US-20040002508-A1 | Antitumor agents; anticancer agents; sexual disorders; cardiovascular disorders | BAYER CORPORATION | 2004-01-01 | — | — | US | disclosed |
| EP-1346977-A1 | Method for producing aryl-aminopropanols | Bayer Aktiengesellschaft (DE) | 2003-09-24 | — | — | EP | disclosed |
| EP-1340746-A1 | Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives | BAYER AG (DE) | 2003-09-03 | — | — | EP | disclosed |
| WO-2003062225-A1 | PYRIMIDINE DERIVATIVES AS RHO-KINASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003062227-A1 | RHO-KINASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
| US-20030096182-A1 | Polyhydroxyalkanoate containing unit with thienyl structure in the side chain, process for its production, charge control agent, toner binder and toner which contain this polyhydroxyalkanoate, and image-forming method and image-forming apparatus which make use of the toner | CANON KABUSHIKI KAISHA (JP) | 2003-05-22 | — | — | US | disclosed |
| EP-1245605-A2 | Polyhydroxyalkanoate containing unit with thienyl structure in the side chain, process for its production, charge control agent, toner binder and toner which contain this polyhydroxyalkanoate, and image-forming method and image-forming apparatus which make use of the toner | CANON KABUSHIKI KAISHA (JP) | 2002-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053179-A1 | Rho-Kinase Inhibitors | CIT, ROCK1, ROCK2 | CYP2C9 2857/4885CYP2C19 1525/4885TSHR 2786/4885 |
| US-20040002508-A1 | Antitumor agents; anticancer agents; sexual disorders; cardiovascular disorders | CIT, ROCK1, RHOT2 | CYP2C9 2702/4885CYP2C19 1383/4885TSHR 3532/4885 |
| US-20120302587-A1 | RHO-KINASE INHIBITORS | CIT, ROCK1, ROCK2 | CYP2C9 2857/4885CYP2C19 1525/4885TSHR 2786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.